Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Pyrazinamide Stories

2012-07-24 11:05:59

Lancet paper finds novel drug regimen could be more effective than existing treatments; TB Alliance's trial to test drugs in combination saves years in research time A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the...

2011-08-11 21:45:22

Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood. Now, researchers have discovered a key reason why the drug effectively shortens the required duration of TB therapy. The finding potentially paves the way for the development of new drugs that can help eliminate TB in an infected individual even more rapidly. The study was supported by the National...

2011-04-13 07:43:06

(Ivanhoe Newswire) -- In patients with newly-diagnosed tuberculosis (TB), use of a combined four-drug, fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a new study. "Despite the availability of a highly effective 6-month chemotherapy regimen, worldwide control of tuberculosis is severely impeded by poor treatment completion rates that threaten the emergence of multidrug resistance," according to background information in the article....

2011-04-12 14:15:21

In patients with newly diagnosed tuberculosis (TB), use of a combined 4-drug fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a study in the April 13 issue of JAMA, a theme issue on infectious disease and immunology. Christian Lienhardt, M.D., M.Sc., Ph.D., of the World Health Organization, Geneva, Switzerland, presented the findings of the study at a JAMA media briefing at the National Press Club. Dr. Lienhardt conducted the study while...

2009-07-30 16:44:53

A typical dose of the medication Pyrazinamide, key to treating tuberculosis, may be too low because of modern-day physiques, U.S. researchers said. Lead author Dr. Tawanda Gumbo of the University of Texas Southwestern Medical Center in Dallas suggests today's TB dosage may not take into account the trend in some societies towards obesity. The researchers propose different doses are probably needed in different countries. What really drives the variability of this particular drug is patient...

df6c638129c48cd87d2dd2b38922411c1
2009-07-30 12:35:00

The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques,UT Southwestern Medical Center researchers said. The finding, reported online and in the August edition of Antimicrobial Agents and Chemotherapy, is particularly important for those living in societies plagued by obesity, said Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and the study's lead author."What really drives...

2009-03-30 11:37:12

The discovery of a large number of slow-growing Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB), in the lungs of TB patients could be an important step forward in the design of new anti-TB drugs.Until now it was thought that M. tuberculosis bacteria in the lungs of TB patients were rapidly multiplying. However recent research by Dr Simon Waddell and colleagues from St George's University of London and the University of Leicester, using gene chips to look at how TB bacteria...

2008-06-17 03:00:10

By Chang, Kwok C Leung, Chi C; Yew, Wing W; Lau, Tat Y; Tam, Cheuk M Rationale: Relatively little is known about the hepatotoxicity of pyrazinamide. Objectives: We compared continuation-phase regimens incorporating pyrazinamide, isoniazid, and/or rifampin with those containing isoniazid and rifampin to evaluate the hepatotoxicity of pyrazinamide. Methods: Cohort and nested case-control analyseswere conducted on a cohort of 3,007 patients with active tuberculosis (TB) managed at government...

2004-11-25 03:00:15

Multidrug-resistant tuberculosis (MDR TB) caused by Mycobacterium tuberculosis resistant to both isoniazid and rifampicin with or without resistance to other drugs is among the most worrisome elements of the pandemic of antibiotic resistance. Globally, about three per cent of all newly diagnosed patients have MDR-TB. The proportion is higher in patients who have previously received antituberculosis treatment reflecting the failure of programmes designed to ensure complete cure of patients...


Latest Pyrazinamide Reference Libraries

72_0ab04c9452ae9b3c6ae51f6deb1bcc35
2011-04-25 16:19:14

Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Robert Koch first discovered it in 1882 and that it had an unusual, waxy coating on the cell surface which makes them impossible to Gram stain. M. tuberculosis is highly aerobic and requires high levels of oxygen. It generally infects the respiratory system of mammals. Tuberculin skin test, acid-fast stain, and chest radiographs are the most...

More Articles (1 articles) »